Our Five Best-Performing Stocks Since the December Monthly Meeting Are Tech-Free
It's been a topsy-turvy start to 2025 for the stock market. Since the Club's monthly meeting in December, Wall Street…
Dow Jones Industrial Average
Palo Alto Stocks Boosted by Contract News, Abbott Labs Braces for Ruling
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
Why Eli Lilly and Palo Alto Networks are keeping up with their competitors
Every weekday, the CNBC Investment Club with Jim Cramer publishes Homestretch, a handy evening update, just in time for the…
We are encouraged by Abbott's stock performance, but discouraged by the moves at Honeywell
Every weekday, the CNBC Investment Club with Jim Cramer publishes Homestretch, a handy evening update, just in time for the…
These are the top pharmaceutical stocks selected by JPMorgan for its results
JPMorgan is eyeing some drugmakers ahead of their earnings reports as investors continue to sell shares of major technology companies.…
A poor earnings report from a competitor is good news for Abbott Labs
Every weekday, the CNBC Investment Club with Jim Cramer hosts a live “Morning Meeting” broadcast at 10:20 a.m. ET. Here’s…
FDA approval of Eli Lilly's Alzheimer's drug cements our decision not to profit
Each weekday, the CNBC Investment Club with Jim Cramer publishes The Home Stretch, a handy evening update, just in time…
The 4 things we're most focused on in the stock market this week
The Nasdaq Composite rose slightly on Friday for its fifth consecutive record close, as new data last week showed a…
Wells Fargo CEO Talks Reasons to Love Stocks, Plus Why the Market is Falling
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
Eli Lilly shares hit new highs after a regulatory victory in China. This is a big problem
Every weekday, the CNBC Investing Club with Jim Cramer hosts a “Morning Meeting” livestream at 10:20 a.m. ET. Here's a…